ANDERS ULFHIELM TAKES OVER AS CEO FOR NICOCCINO HOLDING AB

Anders Ulfhielm will as of September 22nd2016 take over as CEO for Nicoccino
Holding AB. He has long experience in the pharmaceutical industry, most recently
from a position as partner at Avanticon AB.
The change is part of Nicoccino’s strategic focus in achieving a drug approval
of the product that was announced this spring. The current CEO, Johan Cram, will
thereby leave Nicoccino Holding AB.

”I welcome Anders Ulfhielm as CEO to Nicoccino Holding AB and look forward in
continuing to develop the business together with him. He has extensive
experience from both the approval process and planning of production of
pharmaceuticals, which will be of great benefit for the Company. At the same
time I want to thank Johan Cram, who has contributed greatly by adjusting the
Company’s strategy and creating stable financial conditions. He has also
initiated the process of drug classification, and as a consequence, the ramp
down of the consumer business. I wish him all the best in the future.” says
Jonas Nordquist, Chairman of the Board in Nicoccino Holding AB.

Jonas Nordquist, Director of the Board

+46 70 714 2003
jonas.nordquist@nicoccino.se

About Nicoccino Holding AB

Nicoccino AB develops and markets a patented, innovative and discrete nicotine
product that instantly provides the user with nicotine without the detrimental
side effects of traditional tobacco products. The product has the same name as
the company – Nicoccino™ – and is manufactured through partners.

Nicoccino`s head quarter is located in Täby outside of Stockholm. The company's
share has been listed on Nasdaq First North since June 2014 and can be found
under the abbreviation NICO.

Remium Nordic AB is Nicoccino Holding's Certified Adviser.

This information is such information which Nicoccino Holding AB is required to
disclose according to EU’s Market Abuse Regulation. The information was provided
by the above contact person’s auspices, for publication on September 13, 2016 at
08:00.
Johan Cram
CEO

+46 708-980 418
johan.cram@nicoccino.se
Nicoccino has developed a patented, innovative and discrete strip that through
its unique delivery method instantly provides the user with nicotine without the
detrimental side effects of smoking.
The product is designed to offer smokers an attractive alternative when they
want to quit smoking.
After a pharmaceutical approval, the product will be sold as a smoking cessation
drug (Nicotine Replacement Therapy – NRT).